Anika Therapeutics (ANIK) Tops Q3 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $19.45 --0%
EPS Growth %: +950.0%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +950.0%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.00, $0.35 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $38.27 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Fidelity National Information Services, Inc. (FIS) Tops Q3 EPS by 1c ; Offers Guidance
- MoonLake Immunotherapeutics (MLTX) Misses Q3 EPS by 15c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
